Goel Neerja, Malik Ria, Rathi Balkesh, Bhaskaran Sruthi, Rajaram Shalini, Mehta Sumita, Agarwal Nitin
Department of Obstetrics and Gynecology, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, 110095, India.
J Gastrointest Cancer. 2013 Mar;44(1):115-7. doi: 10.1007/s12029-012-9464-4.
Gastrointestinal stromal tumors (GISTs) are among the few cancers amenable to successful treatment by targeted molecular therapy with KIT receptor inhibitors like imatinib mesylate. Increasing incidence of this tumor and its successful treatment has given rise to issues of fertility and child bearing in patients affected at young age. Although contraception advice and termination of early pregnancy have been the standard practice in patients on such therapy, an occasional patient who desires pregnancy can leave both obstetrician and oncologist perplexed.
We report our experience in a rare patient of metastatic GIST who had a successful normal pregnancy while on imatinib therapy. We further attempt to evaluate similar evidence in literature.
胃肠道间质瘤(GISTs)是少数可用甲磺酸伊马替尼等KIT受体抑制剂进行靶向分子治疗而成功治愈的癌症之一。这种肿瘤发病率的上升及其成功治疗引发了年轻患者的生育和妊娠问题。尽管避孕建议和早期妊娠终止一直是接受此类治疗患者的标准做法,但偶尔有希望怀孕的患者会让产科医生和肿瘤学家都感到困惑。
我们报告了1例罕见的转移性GIST患者在接受伊马替尼治疗期间成功正常妊娠的经验。我们还进一步尝试评估文献中的类似证据。